Neurocrine Biosciences - NBIX Competitors

Neurocrine Biosciences (NASDAQ:NBIX) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.

Is NBIX or RGEN more profitable?

Repligen has a net margin of 23.20% compared to Neurocrine Biosciences' net margin of 10.38%. Repligen's return on equity of 10.31% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	10.38%	10.19%	7.13%
Repligen	23.20%	10.31%	7.68%

Does the MarketBeat Community favor NBIX or RGEN?

Neurocrine Biosciences received 543 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 79.64% of users gave Neurocrine Biosciences an outperform vote while only 68.92% of users gave Repligen an outperform vote.

Company	Underperform	Outperform
Neurocrine Biosciences	Outperform Votes 931 79.64%	Underperform Votes 238 20.36%
Repligen	Outperform Votes 388 68.92%	Underperform Votes 175 31.08%

Which has preferable earnings & valuation, NBIX or RGEN?

Repligen has lower revenue, but higher earnings than Neurocrine Biosciences. Repligen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$1.49 billion	6.57	$154.50 million	$1.53	66.16
Repligen	$801.54 million	11.69	$185.96 million	$3.25	51.80

Do analysts rate NBIX or RGEN?

Neurocrine Biosciences currently has a consensus target price of $126.00, suggesting a potential upside of 24.48%. Repligen has a consensus target price of $218.50, suggesting a potential upside of 29.78%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.69
Repligen	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media favor NBIX or RGEN?

In the previous week, Neurocrine Biosciences had 5 more articles in the media than Repligen. MarketBeat recorded 9 mentions for Neurocrine Biosciences and 4 mentions for Repligen. Neurocrine Biosciences' average media sentiment score of 0.91 beat Repligen's score of 0.63 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, NBIX or RGEN?

Neurocrine Biosciences has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of NBIX or RGEN?

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 91.0% of Repligen shares are held by institutional investors. 4.4% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 1.1% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Neurocrine Biosciences and Repligen tied by winning 9 of the 18 factors compared between the two stocks.